1404-0043 Trial Investigators
Need for Medical Supervision GLP-1 microdosing should never be attempted without proper medical guidance
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
The following timeline, based on clinical trial data from Eli Lilly, shows the typical progression: Appetite suppression typically begins around day 3 of the first dose, with significant feelings of fullness developing by week 2
Semaglutide, suicidal ideation and behaviour: a resting state functional magnetic resonance imaging perspective
.png.jpg)
